Summary.-Levamisole has been examined for its ability to control local growth and pulmonary metastases of transplanted rat tumours. The compound did not suppress subcutaneous growth of 3-methylcholanthrene induced sarcomata when administered systemically in a variety of regimens, or when injected in admixture with tumour cells. In addition, levamisole treatment failed to suppress pulmonary growth of intravenously transferred sarcoma cells or spontaneous pulmonary metastases appearing after surgical removal of a transplanted epithelioma.
LEVAMISOLE EXHIBITS a wide variety of immunostimulatory properties, adjuvanting humoral and cellular immunity Renoux, 1971, 1972a; Potter et at., 1974) , restoring immunological reactivity in aged animals (Renoux and Renoux, 1972b) and skin test hypersensitivity in man, including cancer patients, where cell mediated immunity is impaired (Tripodi, Parks and Brugmans, 1973; Hirshaut et al., 1973; Verhaegen et al., 1973) . In addition, levamisole treatment stimulates macrophage functions in man and animals (Verhaegen et al., 1973; Hoebeke and Franchi, 1973) , increasing phagocytosis without hyperplasia or hypertrophy of the reticuloendothelial system. These properties of levamisole have encouraged its evaluation as an immunotherapeutic agent in the treatment of both experimental and human tumours. Thus, Renoux and Renoux (1972c) reported that levamisole treatment of mice receiving subcutaneous grafts of the Lewis lung carcinoma prevented local tumour development and reduced the incidence of pulmonary metastases. Clinically, Amery (1975) has reported beneficial effects of levamisole treatment in patients with resectable bronchogenic carcinoma, while Webster and Hughes (1975) are currently treating patients with malignant melanoma and carcinomata of the stomach and colon.
In contrast to the initial report by Renoux and Renoux (1972c) with the Lewis lung carcinoma, however, more recent experimental studies with other tumour types have failed to confirm the tumour suppressive action of levamisole. Thus, Potter et al. (1974) were unable to suppress local growths or pulmonary metastases with a range of 4 virus or chemically induced mouse, rat and hamster tumours by levamisole administration, while treatment significantly enhanced growth of an adenovirus 12-induced tumour. With the rat Walker 256 tumour, repeated levamisole treatment did not suppress tumour transplants (Flannery, Rolland and Nairn, 1975) and treatment was also without influence on growth of a transplanted Moloney lymphoid leukaemia in mice (Chirigos, Pearson and Pryor, 1973) (Baldwin, 1966) and is weakly immunogenic so that immunized rats can reject challenge with only 5 x 104 cells. This tumour regularly produces pulmonary metastases from subcutaneous growths, even following their surgical removal (Baldwin and Pimm, 1973a Levamisole.-Levamisole (2,3,5,6-tetrahydro-6-phenyl imidazo (2,16) thiazole) was supplied by Janssen Pharmaceutica, Beerse, Belgium. The compound was dissolved in physiological saline and the solution sterilized by passage through a 0-22 ,m Millipore filter.
Methods of treatment.-Rats (150-200 g body weight) receiving subcutaneous or intravenous challenge inocula of sarcoma cells were treated by single or repeated administration of levamisole at 5 to 20 mg/kg body weight given intraperitoneally, subcutaneously, intravenously by a lateral tail vein, or orally by intra-oesophageal gastric instillation. With epithelioma Spl, 9-14 day old subcutaneous tumour growths were removed surgically under ether anaesthesia, and rats treated with 4-6 intravenous injections of levamisole (5 mg/kg) starting one day after surgery.
In some tests with sarcomata Mc7 and Mc57, tumour cells were injected subcutaneously in admixture with levamisole solution (1-5 mg levamisole/inoculum).
Assessment of tumour growth.-Subcutaneously developing tumours were measured with calipers twice weekly and a mean diameter calculated from measurements in two planes. Animals receiving intravenously injected sarcoma cells, or from which epithelioma Spl grafts had been excised, were killed individually when exhibiting respiratory distress caused by growth of tumours in the lungs. Statistical significance of the difference in survival between treated and control rats was assessed by the Wilcoxon nonparametric rank test. Pulmonary tumour growths and spontaneous pulmonary metastases were visualized by perfusion of lungs with dilute India ink (Wexler, 1966) and the number of macroscopically visible discrete surface growths counted. Greater than 200 pulmonary deposits were scored as 200+.
RESUILTS Treatment of subcutaneous tumotur growvths
In the first series of tests, subcutaneous growths of sarcomata Mc57 and Mc7, initiated by injection of 1 X 106 tumour cells, were treated by repeated administration of levamisole. These experiments were designed to examine a number of variables, including different dose schedules (5-20 mg/kg body weight), routes of administration and time of initiation of treatment (Table I) . In no case, however, did these treatments either prevent tumour appearance or retard their progressive growth, in comparison with untreated control rats. In 3 further tests (Table II) , the influence of localized levamisole on subcutaneous tumour development was assessed by injecting tumour cells in direct admixture with the agent, but again there was no inhibition of tumour growth with either sarcoma.
Treatment of post-sargical metastases Table III shows the influence of levamisole treatment on the development of pulmonary metastases appearing after surgical excision of the transplanted epithelioma Spl. In these tests small subcutaneous tumour growths (mean diameter 1-2 cm) were removed surgically and rats treated by 4-6 intravenous injections of levamisole at 5 mg/kg/injection, starting one day after tumour excision. In the first test untreated animals all had to be killed 28 days after initial tumour implan- 3, 37, 82, 89, 150, 170 3, 7, 22, 80, 
DISCUSSION
The present studies demonstrate that repeated systemic administration of levamisole at up to 20 mg/kg/injection by a variety of routes exerts no suppressive effect on growth of highly immunogenic 3-methylcholanthrene (Mc) induced sarcomata. Treatment also failed to affect the post-surgical survival of rats from which subcutaneous grafts of the weakly immunogenic epithelioma Spl had been excised. A small anti-tumour effect was, however, obtained by repeated administration of the drug at 5 mg/kg to animals receiving intravenous challenge inocula of the sarcoma Mc57, as reflected in a prolongation of survival in one of two tests.
The comparative ineffectiveness of levamisole in the treatment of rat tumours described in this paper is in contrast to the report by Renoux and Renoux (1972c) where a single inijection of as little as 0 5 mg/kg into mice receiving grafts of the Lewis lung tumour completely prevented subcutaneous tumour development in a proportion of animals and significantly reduced the development of pulmonary metastases. However, in other similar studies Potter et al. (1974) founid that repeated levamisole injections at the same dose (0.5 ing/kg) failed to influence the growth of a transplanted CELO-virus induced hamster tumour, a Moloney virus induced mouse lymphoma, or the incidence of primary and metastatic growth of a chemically induced transplanted rat tumour. Furthermore, treatment significantly enhanced growth of a transplanted adenovirus 12 induced hamster tumour (Potter et al., 1974) and was without influence on growth of Walker 256 tumour in rats (Flannery et al., 1975) .
In addition to its general immunostimulatory properties, levamisole stimulates macrophage functions in man and animals (Verhaegen et al., 1973; Hoebeke and Franchi, 1973) , activating phagocytosis without hyperplasia or hypertrophy of the reticuloendothelial system. It is well established (reviewed by Laucius et al., 1974) that Bacillus CalmetteGuerin (BCG) organisms when injected in direct admixture with tumour cells may suppress their growth. This effect is most probably mediated by local activation of macrophages since it can be abrogated by silica-induced host macrophage depletion (Pimm and Hopper, 1975) . In the present studies, therefore, tests were carried out to examine the tumour suppressive action of levamisole when it, too, was injected directly in admixture with tumour cells, but again the compound did not suppress the growth of either of two Mc induced sarcomata. This finding contrasts markedly with previous studies employing locally administered BCG. Here, pronounced suppressive effects were achieved by the introduction of viable or radiation killed BCG directly into the site of tumour growth, either subcutaneously in admixture with tumour cells Pimm, 1971, 1973b; Baldwin et al., 1974) , or into pulmonary tissue by intravenous injection to control growth of pulmonary tumour growths, including post-surgical metastases from the epithelioma Spl (Baldwin and Pimm, 1973a, c) .
A further property of levamisole is its ability to restore immunological reactivity in aged animals and anergic patients (Renoux and Renoux, 1972b; Tripodi et al., 1973; Hirshaut et al., 1973; Verhaegen et at., 1973) . In this context, Chirigos et al (1973) reported that while levamisole alone had no effect on growth of a Moloney virus induced murine leukaemia, marked protective effects were achieved when the drug was administered during BCNU induced tumour remission. This synergistic effect between conventional chemotherapy and levamisole treatment has been interpreted as due to early restoration of cell mediated immunity, destroying remaining tumour cells when at a minimal level (Perk et al., 1975) . Similar tests are in progress to assess the combined effects of levamisole and chemotherapeutic agents in the treatment of the rat tumours described in this paper. However, the conclusion from the present studies is that levamisole, while reported to have a broad spectrum of immunological effects, may not necessarily be as effective as other adjuvants if used alone as an immunotherapeutic agent, and further experimental studies may be needed to form a rational basis for a clinical application of the compound.
